Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Join | Sign in
Home>Videos>This Video
  Videos

Return

Webinar:
Advance drug discovery by improving dose-response curve set-up

Tecan Group Ltd.

Richard Marcellus, Molecular Biologist, Ontario Institute for Cancer Research Save time and reduce waste while improving data quality for small molecule dose-response curves Titration of small molecules in DMSO is a ubiquitous part of the drug discovery workflow. Traditional methods require serial dilution which can be wasteful in terms of tips, intermediate plates and compounds. This process is also time consuming, and reproducibility from researcher to researcher can be a challenge. Traditionally, laboratories have had to accept the potential for carry-over and accumulated pipetting errors, as well as the high labor costs associated with this task. In addition, many laboratories are not performing scientifically optimal titrations, due to equipment or time restrictions. For example, in vitro drug-drug interaction experiments are often desired, but are too complicated to perform routinely. Low- and medium-throughput laboratories, such as therapeutic or lead optimization departments, cannot always justify the purchase of large automation equipment. Not only can the cost of these systems be prohibitive, they can also impose undesirable limits on assay set-up, and often require specialist knowledge to maintain and program. These laboratories need an affordable solution that meets their demands for flexibility, speed and reliability. Join our webinar as we examine the potential for change in dose-response curve set-up for small molecules in DMSO, leading to time savings and dose and plate layout flexibility for drug discovery biologists. Key Learning Objectives • Explore methods to save time and reduce labor costs when setting up dose-response curves • Save precious compounds and eliminate waste of consumables and reagents • Quickly set up drug-drug interaction experiments, along with other complex plate layouts • Improve data quality in dose-response curves and decrease the number of bioassay wells required Richard C. Marcellus, Ph.D. Biochemist - Ontario Institute for Cancer Research, Toronto, Canada Richard has spent over a decade working in cancer drug discovery and has broad experience ranging from target identification, to assay development and HTS, SPR-based protein-drug interaction analysis, and drug target validation. He currently works in the Medicinal Chemistry Group at the OICR, a translational research institute. Richard runs in vitro assays in support of SAR programs, and has embarked upon a targeted screening program in patient-derived primary cancer cells. In this study drug sensitivity is being combined with RNAi and deep sequencing to identify promising anti-cancer targets.

Request more information
Company product page


Access to this article and other content is for registered users.

Join the Technology Networks Community

  • Access to the latest scientific news, products and research through Technology Networks
  • Upload and share your posters on ePosters
  • View a library of 1,800+ scientific and medical posters
  • A library of 3,000+ scientific videos on LabTube


Sign In



Forgotten your details? Click Here
If you already have an account with Technology Networks, please use your existing login details. If you do not yet have an account please join here.

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
NIH Launches Largest Clinical Trial Focused on HIV-related Cardiovascular Disease
Clinical trial to test whether statin administration can reduce the risk for major adverse cardiovascular events.
No Evidence to Change Current Transfusion Practices for Adults
Study found no difference in the primary clinical measure between complex cardiac surgery patients.
Personalized Melanoma Vaccines Marshal Powerful Immune Response
Vaccines target unique mutations in each patient’s tumor.
Repurposed Experimental Cancer Drug Restores Brain Function in Mouse Models
NIH-supported research enables clinical trial to explore treatment for most common form of dementia.
Experimental Ebola Vaccine Safe, Prompts Immune Response
Results from US government-sponsored phase 1 trial of VSV vaccine reported.
Ebola Test Vaccines Appear Safe in Phase 2 Liberian Clinical Trial
Liberia-U.S. partnership planning Phase 3 trial and study of Ebola survivors.
NIH Works to Improve Kidney Health for All
Statement of NIDDK Director Griffin P. Rodgers, M.D., for World Kidney Day 2015.
MorphoSys and Emergent BioSolutions Initiate Phase 1 Clinical Study
Phase 1 study to evaluate the novel oncology immunotherapeutic MOR209/ES414 for prostate cancer.
NIH-supported Clinical Trials to Evaluate Long-acting, Injectable Antiretroviral Drugs
Both trials are expected to be completed in 2017.
Single-Cell, 42-plexed Protein Analysis Achieved with a New Microchip Technology
A novel microdevice capable of detecting 42 unique immune effector proteins has been developed.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters